FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Roti patents



      
           
This page is updated frequently with new Roti-related patent applications. Subscribe to the Roti RSS feed to automatically get the update: related Roti RSS feeds. RSS updates for this page: Roti RSS RSS


Fusion polypeptides and methods of use thereof

Trustees Of Columbia University In City Of New York

Fusion polypeptides and methods of use thereof

Fusion polypeptides and methods of use thereof

Silk Road Medical

Transcarotid neurovascular catheter

Date/App# patent app List of recent Roti-related patents
06/25/15
20150177244
 Parallel analysis of serum epcam and mmp7 to discriminate sepsis, necrotizing enterocolitis and normal control patients patent thumbnailnew patent Parallel analysis of serum epcam and mmp7 to discriminate sepsis, necrotizing enterocolitis and normal control patients
Methods and compositions are provided for making a necrotizing enterocolitis (nec) or sepsis assessment of an individual. Aspects of the methods include detecting a biomarker or panel of biomarkers selected from mmp7, epcam, and crp.
The Board Of Trustees Of The Leland Stanford Junior University
06/25/15
20150176003
 Euglobulin-based  determining the biological activity of defibrotide patent thumbnailnew patent Euglobulin-based determining the biological activity of defibrotide
It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 iu/mg of defibrotide, preferably from 27.5 to 32.5 iu/mg and, more preferably, from 28 to 32 iu/mg..
Gentium S.p.a.
06/25/15
20150175675
 Fusion polypeptides and methods of use thereof patent thumbnailnew patent Fusion polypeptides and methods of use thereof
The present invention also provides fusion polypeptides with a carboxy-terminal or n-terminal peptide domain (e.g., fc, ctp, or fc-ctp), and nucleic acid molecules encoding these polypeptides. The present invention further provides for methods of using the compositions of the invention for treatment of cancer and fibrotic diseases.
The Trustees Of Columbia University In The City Of New York
06/25/15
20150175597
 Apoptosis signal-regulating kinase inhibitors patent thumbnailnew patent Apoptosis signal-regulating kinase inhibitors
The present application relates to compounds having the inhibitory activity to apoptosis signal-regulating kinase (ask1), thus are thus useful in treating ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases.. .
Gilead Sciences, Inc.
06/25/15
20150174368
 Transcarotid neurovascular catheter patent thumbnailnew patent Transcarotid neurovascular catheter
An interventional catheter for treating an artery includes an elongated body sized and shaped to be transcervically introduced into a common carotid artery at an access location in the neck. The elongated body has an overall length such that the distal most section can be positioned in an intracranial artery and at least a portion of the proximal most section is positioned in the common carotid artery during use..
Silk Road Medical, Inc.
06/25/15
20150174266
 Aprotinin polypeptides for transporting a compound across the blood-brain barrier patent thumbnailnew patent Aprotinin polypeptides for transporting a compound across the blood-brain barrier
The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates.
Angiochem Inc.
06/25/15
20150174183
 Methods and pomegranate extract composition for treating diabetes related atherosclerotic complications in humans patent thumbnailnew patent Methods and pomegranate extract composition for treating diabetes related atherosclerotic complications in humans
One or more embodiments of the invention are directed to methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans. The methods comprise the step of administering to the patients a composition comprising a therapeutically effective amount of an extract from pomegranate..
Pom Wonderful, Llc
06/25/15
20150173782
 Methods and systems for treatment of acute ischemic stroke patent thumbnailnew patent Methods and systems for treatment of acute ischemic stroke
A system of devices for treating an artery includes an arterial access sheath adapted to introduce an interventional catheter into an artery and an elongated dilator positionable within the internal lumen of the sheath body. The system also includes a catheter formed of an elongated catheter body sized and shaped to be introduced via a carotid artery access site into a common carotid artery through the internal lumen of the arterial access sheath.
Silk Road Medical, Inc.
06/18/15
20150164907
 Compositions and methods for treating disease patent thumbnailCompositions and methods for treating disease
Methods are provided for treating fibrotic diseases and conditions or cancer and other dysproliferative diseases by administering to a subject in need there of a therapeutically effective amount of a synergistic composition comprising a phosphatidylinositol 3-kinase inhibitor and a retinoid, optionally including a cyp26 inhibitor, wherein the therapeutically effective amount suppresses fibrosis or the growth of dysproliferative cells in vivo. Compositions comprising a combination of a phosphatidylinositol 3-kinase inhibitor and a retinoid, optionally in combination with a cyp26 inhibitor, are also described..
Angion Biomedica Corp.
06/11/15
20150158813
 Substituted 3-haloallylamine inhibitors of assao and uses thereof patent thumbnailSubstituted 3-haloallylamine inhibitors of assao and uses thereof
Is described. Methods of using compounds of formula i, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described..
06/11/15
20150157477

Device for endovascular aortic repair and using the same


An intraluminal vascular prosthesis assembly, having a hollow cylindrical body with a first end and a second end is provided. The assembly includes, at its first end, a first vascular prosthesis portion, and at its second end, a second vascular prosthesis portion which has only a prosthesis material.
Aortic Innovations, Llc
06/11/15
20150157346

Restoring blood flow and clot removal during acute ischemic stroke


Devices for restoring blood flow to facilitate lysis of clots and/or enable capture of clots are disclosed. The devices can be configured to be disposed within a lumen of a microcatheter that is inserted within neurovasculature above a carotid siphon to a location of a clot.
Covidien Lp
06/04/15
20150152102

Piperidinylpyrazolopyridine derivative


A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-hdl-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein r is an optionally substituted aryl group or an optionally substituted heteroaryl group.. .
Daiichi Sankyo Company, Limited
06/04/15
20150150562

Method and treating a carotid artery


One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery..
Silk Road Medical, Inc.
05/28/15
20150148682

Non-contact thermometer sensing a carotid artery


Systems, methods and apparatus are provided through which in some implementations a non-contact thermometer determines a temperature of a subject from a carotid source point of the subject.. .
Brooklands, Inc.
05/21/15
20150141760

Systems and methods for treating a carotid artery


Systems and methods are adapted for treating the carotid artery. The systems include interventional catheters and blood vessel access devices that are adapted for transcervical insertion into the carotid artery.
Silk Road Medical, Inc.
05/21/15
20150141501

Ultrapure tetrahydrocannabinol-11-oic acids


This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceutics Inc.
05/21/15
20150140161

Methods of improving tolerance related to feeding in an infant, toddler, or child


Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component..
Abbott Laboratories
05/21/15
20150137032

Process for producing heat-treated vinylidene fluoride polymer powder and process for producing vinylidene fluoride polymer solution


The present invention relates to a process for producing a vinylidene fluoride polymer solution, which involves dissolving heat-treated vinylidene fluoride polymer powder into an aprotic polar solvent. The heat-treated vinylidene fluoride polymer powder is obtained by heat treating raw vinylidene fluoride polymer powder at such a temperature that the temperature of the vinylidene fluoride polymer powder is not less than 125° c.
Kureha Corporation
05/14/15
20150132466

Nutritional products including a novel fat system including fatty acids


Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component..
05/14/15
20150131889

Necrotic cell region detection apparatus and the same, and non-transitory computer readable storage medium to store a necrotic cell region detection program


A necrotic cell region detection apparatus includes an image acquiring unit, a segmentation unit, a band separate unit, a feature value calculating unit, a luminance calculating unit, and a judging unit. The image acquiring unit acquires a cell image.
05/07/15
20150127068

Nerve stimulator system


Devices, systems and methods for applying electrical impulse(s) to one or more selected nerves are described. An electrical stimulator is introduced through a to a target location within, adjacent to, or in close proximity with, the carotid sheath.
Electrocore, Llc
05/07/15
20150126622

Blood biomarkers for necrotizing enterocolitis


Necrotizing enterocolitis (nec) biomarkers, nec biomarker panels, and methods for obtaining a nec signature for a sample are provided. Also provided are methods, compositions, and kits for making a necrotizing enterocolitis (nec) assessment of an individual, e.g.
The Board Of Trustees Of The Leland Stanford Junior University
04/30/15
20150119576

Method for production of 3-hydroxypropan-1-one compound, production of 2-propen-1-one compound and production of isoxazoline compound


There is provided a novel intermediate for producing pesticides. A method for producing the compound of formula (3) comprises reacting an aromatic ketone compound of formula (4) and a substituted acetophenone compound of formula (5) as starting raw materials in an organic solvent or water in the presence or absence of an additive in the presence of a base in a suspended state.
Nissan Chemical Industries, Ltd.
04/30/15
20150118698

Biochemical markers for cvd risk assessment


A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events..
Nordic Biociences A/s
04/30/15
20150118309

Preparation for percutaneous absorption containing rotigotine


Exemplary embodiments of the present invention relate to a method for preparing a preparation for percutaneous absorption, which includes rotigotine as an active ingredient, and more specifically, to a method for preparing a preparation for percutaneous absorption including mixing rotigotine and an ethylene-vinyl acetate adhesive so as to have a weight ratio of 1:(0.1 to 20), a preparation for percutaneous absorption manufactured by the method, and a percutaneous treatment system. The preparation and the system may prevent separation of the rotigotine, thereby increasing long-term storage stability, and effectively release the rotigotine, and thus can be effectively applied to preparing patch medication containing the rotigotine..
Sk Chemicals Co., Ltd.
04/30/15
20150118282

Transdermally absorbable preparation containing rotigotine


A method for preventing the precipitation of rotigotine crystals, including a step of mixing rotigotine and one or more crystallization prevention agents selected from the group consisting of fatty alcohols, fatty acids, fatty acid esters, fatty acid amides, and the derivatives thereof, and to a transdermally absorbable preparation that includes rotigotine and crystallization prevention agents.. .
Sk Chemicals Co., Ltd.
04/23/15
20150112359

Electrical stimulation of the carotid artery


In order to treat hypertension, an implantable receiving device is connected to implantable leads which are adapted to deliver electrical energy to the carotid body or bodies of the patient. The receiving device is arranged to receive electoral energy from an external generator.
Bioinduction Limited
04/23/15
20150111947

Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage


Provided herein are methods of decreasing leukocyte extravasation from a lymph or blood vessel into a tissue in a mammal, methods of decreasing fluid leakage from a lymph or blood vessel in a mammal in need thereof, methods of decreasing formation of atherosclerotic plaques in a mammal in need thereof, and methods of treating atherosclerosis in a mammal that include administering to the mammal an oligonucleotide that decreases mitogen-activated protein kinase kinase kinase kinase 4 (map4k4) mrna expression in an endothelial cell. Also provided are methods of identifying a candidate agent useful for decreasing leukocyte extravasation or decreasing fluid leakage from a lymph or blood vessel in a mammal, and compositions containing an oligonucleotide that decreases map4k4 mrna expression in an endothelial cell and additional therapeutic agents..
University Of Massachusetts
04/23/15
20150111872

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.. .
04/23/15
20150111824

Pharmaceutical formulations comprising incretin mimetic peptide and aprotic polar solvent


The present disclosure is directed to stable pharmaceutical formulations and uses thereof.. .
Astrazeneca Pharmaceuticals Lp
04/23/15
20150110895

Methods of treating necrotic enteritis


Methods of treating necrotic enteritis are provided, such methods not requiring the use of systemic drugs that have shown to (i) provide slow relief, (ii) cause adverse side effects, (iii) limit activities, (iv) worsen existing gastrointestinal conditions, (v) be unrecommended in several gastrointestinal conditions that include gastrointestinal spasms, or (vi) be unrecommended in the absence of diarrhea.. .
Liveleaf, Inc.
04/16/15
20150104462

Use of semaphorin-4d binding molecules for treatment of atherosclerosis


Provided herein are methods for reducing, inhibiting, suppressing and/or delaying atherosclerotic plaque growth or neovascularization in a subject having atherosclerosis, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4d (sema4d) or to its high affinity plexin-b1 receptor.. .
Vaccinex, Inc.
04/09/15
20150099919

Control of magnetic rotors to treat therapeutic targets


A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources.
Pulse Therapeutics, Inc.
04/02/15
20150094465

N-alkoxyamide conjugates as imaging agents


The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided.
Lantheus Medical Imaging, Inc.
04/02/15
20150094384

Methods for predicting and treating necrotizing enterocolitis in neonates


Embodiments are presented herein that provide early prediction of the development of necrotizing enterocolitis by a preterm infant through analysis of the high frequency component of heart rate variability, optionally with analysis of respiration rate. Methods of treatment following prediction area also reported..
The Penn State Research Foundation
03/26/15
20150086627

Dosage forms of halofuginone and methods of use


Oral and parenteral dosage forms comprising halofuginone, including enteric-coated solid oral dosage forms, subcutaneous dosage forms and intravenous dosage forms, for administration to subjects in need thereof, e.g., subjects having been identified with musculoskeletal disorders, fibrotic diseases, malaria, or cancer are described herein.. .
Halo Therapeutics, Llc.
03/26/15
20150086596

Organophosphates for treating afflictions of the skin


Embodiments of the invention involve treating skin afflictions by the topical or oral use of organophosphates. By effectively reducing or eliminating the population of demodex mites in affected skin areas and areas where demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the skin afflictions than any previously described method.
03/26/15
20150086529

Therapeutic burn gel


Therapeutic radiation burn gel is an invention that promotes the healing of radiated skin. It works by softening the layers of necrotic tissue which form (in the skin) post radiation.
03/26/15
20150086515

Imaging-aided gene therapy using mesenchymal stem cells as target-delivery vehicle


Compositions and methods of use thereof encompass engineered mesenchymal stem cells as a vehicle to deliver secreted tissue necrosis factor-rgd4c fusion polypeptides for tumor treatment, thereby reducing side effects of tnf. A reporter gene can be included in vector constructs to monitor the localization and viability of engineered mscs after administration into a recipient animal.
The Board Of Trustees Of The Leland Stanford Junior University
03/19/15
20150080686

Atherosclerotic plaque detection


An apparatus detects atherosclerotic plaques. The apparatus includes an electronic processing device that determines a level of fluorescence sensed by a sensor at a second infrared wavelength in response to exposure of at least part of an artery to radiation at a first infrared wavelength and determines a fluorescence indicator using the level of fluorescence.
Baker Idi Heart & Diabetes Institute Holdings Limited
03/19/15
20150080320

Multi-target modulation for treating fibrosis and inflammatory conditions


The present invention relates to compositions comprising one or more active agents that selectively modulate the expression of two or more genes, for example at the post-transcription level, that are involved in fibrosis and/or inflammatory conditions. Also provided are methods of using such compositions for treating fibrotic diseases, as well as other diseases including inflammatory diseases and cancer..
Aadigen, Llc
03/19/15
20150079055

Use of secretor, lewis and sialyl antigen levels in clinical samples as predictors of risk for disease


An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the h-1, h-2, lewisb and lewisy antigens and derivatives thereof (e.g., a sialylated form of lewis a, lewis x, lewis b, lewis y; h-1, h-2, lewis a, lewis x, lewis b or lewis y)..
Instituto Nacional De Ciencias Medicas Y Nutricion
03/19/15
20150078997

N-alkoxyamide conjugates as imaging agents


The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided.
Lantheus Medical Imaging, Inc.
03/12/15
20150073400

Tissue treatment


There is provided in accordance with an exemplary embodiment of the invention a method and/or a device of treating tissue near a first lumen comprising inserting an energy emission element into a second lumen and delivering energy in an amount sufficient to cause one or more spaced apart areas of tissue damage at preselected locations in tissue near the first lumen. There is also provided a method and/or a device for treating a carotid artery wall, for example, to reduce signal conduction.
Cardiosonic Ltd.
03/12/15
20150072962

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis


5-cholesten, 3β, 25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virgini Commonwealth University
03/05/15
20150065947

Cell-seeded compositions and methods useful for treating bone regions


Compositions and methods for treating diseased or damaged bone, preferably ischemic and/or necrotic bone, include the use of a combination of endothelial progenitor cells and mesenchymal stem cells, desirably also in conjunction with a collagenous extracellular matrix tissue. Methods for preparation of such compositions are also described..
Muffin Incorporated
02/26/15
20150057216

Angiotensins for treatment of fibrosis


The present invention provides, among other things, methods and compositions for treating or preventing fibrotic diseases, disorders or conditions based on angiotensin (1-7) polypeptides, and analogs or derivatives thereof. In some embodiments, compositions and methods for treating or preventing pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (copd), asthma, cystic fibrosis, kidney fibrosis, liver fibrosis, systemic sclerosis, post-surgical adhesions, accelerating wound healing, and reducing or preventing scar formation are provided..
Tarix Pharmaceuticals Ltd.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Roti for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Roti with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





1.565

3677

459399 - 0 - 72